GlassScriptPhysician profile
Brandon Boyd Johnson
NPI 1386806693
$2,855.34
in general payments reported to CMS, 2019-2025
23 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $37.79 · 2021: $819 · 2022: $735 · 2023: $385 · 2024: $152 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $388.50 | 2021-2023 | Cequa |
| Genentech USA, INC. | $358.81 | 2021-2022 | |
| Alcon Vision LLC | $273.44 | 2022-2025 | Clareon Panoptix Pro, Unity |
| Mallinckrodt Hospital Products INC. | $217.00 | 2021-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $216.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $215.72 | 2019-2021 | |
| Abbvie INC. | $179.83 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $163.01 | 2019-2025 | Eylea, Eylea Hd |
| Bausch & Lomb Americas INC. | $103.23 | 2022-2023 | Vyzulta |
| Aerie Pharmaceuticals, INC. | $101.67 | 2021 | |
| Ani Pharmaceuticals, INC. | $93.92 | 2025 | Yutiq, Iluvien |
| Oyster Point Pharma, INC. | $66.86 | 2023 | Tyrvaya |
| Regeneron Pharmaceuticals, INC. | $63.05 | 2024 | Eylea Hd, Eylea |
| Eyevance Pharmaceuticals LLC | $61.44 | 2021-2022 | |
| Harrow Eye, LLC | $58.88 | 2025 | Iheezo, Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $56.50 | 2022-2023 | Tearcare System |
| Alimera Sciences, INC. | $52.66 | 2019 | |
| Eyepoint US, INC. | $46.94 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $43.82 | 2022 | |
| Optos, INC. | $30.31 | 2019-2020 | |
| Dompe US, INC. | $25.68 | 2025 | Oxervate |
| Allergan, INC. | $19.18 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.